Literature DB >> 24647425

Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.

Wenwen Sui1, Yueying Zhang1, Zhaopeng Wang1, Zhaoxia Wang1, Qing Jia1, Licun Wu2, Weidong Zhang1.   

Abstract

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has recently been shown to affect the development of different types of cancer. The present study utilized a murine H22 hepatocarcinoma model to investigate the molecular mechanisms involved in celecoxib-induced inhibition of tumor angiogenesis. Tumor-bearing mice were randomly divided into five groups: i) control; ii) low-dose celecoxib (50 mg/kg); iii) high-dose celecoxib (200 mg/kg); iv) 5-fluorouracil (5-FU), (20 mg/kg) and v) combination of 5-FU and celecoxib (50 mg/kg). The antitumor effect of celecoxib was determined by measuring tumor volume. Tumor angiogenesis was evaluated by microvessel density (MVD). Tumor histology and immunostaining for CD34 in endothelial cells were performed to detect MVD. The expression levels of phosphatase and tensin homologue deleted from chromosome 10 (PTEN), phosphatidylinositol 3-kinase (PI3K), phospho‑Akt (P-Akt), COX-2, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor-A (VEGF-A) were detected by ELISA, immunohistochemistry and western blotting, respectively. We discovered substantial growth delay in murine H22 hepatoma as a result of celecoxib treatment. The inhibition rate of tumor growth induced by high-dose and low-dose celecoxib was 49.3 and 37.0%, respectively (P<0.05). The expression of PI3K, P-Akt, COX-2, HIF-1α, VEGF-A and PTEN in tumor tissues treated with celecoxib was demonstrated by immunohistochemistry, and the MVD was decreased in a dose-dependent manner (P<0.05). Reduced PI3K and P-Akt was particularly apparent in the high-dose celecoxib group (P<0.05). ELISA and western blotting data showed that the expression of PI3K, P-Akt, COX-2, HIF-1α and VEGF-A were reduced and PTEN was increased after treatment with celecoxib. In conclusion, the impact of celecoxib-induced tumor growth delay of murine H22 hepatocarcinoma may correlate with the inhibition of angiogenesis by reducing PI3K, P-Akt, COX-2, HIF-1α and VEGF-A expression and increasing PTEN expression in tumor tissue.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647425     DOI: 10.3892/or.2014.3093

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Janet S Rader; Michael W Sill; Jan H Beumer; Heather A Lankes; Doris Mangiaracina Benbrook; Francisco Garcia; Connie Trimble; J Tate Thigpen; Richard Lieberman; Rosemary E Zuna; Charles A Leath; Nick M Spirtos; John Byron; Premal H Thaker; Shashikant Lele; David Alberts
Journal:  Gynecol Oncol       Date:  2017-03-10       Impact factor: 5.482

2.  Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells.

Authors:  Fatma M Abdallah; Maged W Helmy; Mohamed A Katary; Asser I Ghoneim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-28       Impact factor: 3.000

3.  Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Authors:  Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme; Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-08-27

4.  COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression.

Authors:  Longhui Zhang; Sufen Li; Lan Li; Zhengqiong Chen; Ying Yang
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

5.  Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway.

Authors:  Meng-Xue Sun; Xiao-Pu He; Pei-Yun Huang; Qi Qi; Wei-Hao Sun; Gao-Shuang Liu; Jie Hua
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

6.  Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Diana Elena Olteanu; Eva Fischer-Fodor; Virag Piroska; Mihai Lupu; Tudor Călinici; Roxana Maria Decea; Gabriela Adriana Filip
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

7.  Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation.

Authors:  Bo Zhang; Youyou Yan; Yangling Li; Dan Zhang; Jianmei Zeng; Linling Wang; Mimi Wang; Nengming Lin
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

8.  Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.

Authors:  Huan Tong; Bo Wei; Shuang Chen; Yong-Mei Xie; Ming-Guang Zhang; Lin-Hao Zhang; Zhi-Yin Huang; Cheng-Wei Tang
Journal:  Oncotarget       Date:  2017-07-18

9.  Melittin Inhibits Hypoxia-Induced Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition through Suppression of HIF-1α/Akt Pathway in Liver Cancer.

Authors:  Qunwei Chen; Wanfu Lin; Zifei Yin; Yong Zou; Shufang Liang; Shanming Ruan; Peifeng Chen; Shu Li; Qijin Shu; Binbin Cheng; Changquan Ling
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-01       Impact factor: 2.629

Review 10.  Common Variants of the Prostaglandin-Endoperoxide Synthase 2 Gene and Hepatocellular Carcinoma Susceptibility.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.